SCHEMBL14815146

SCHEMBL14815146

FC(F)(F)c1ccc(N2CCN3CC[C@@H](Oc4ccc(Cl)cn4)[C@H]3C2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR3 P29371 1/20 0.47
▸ SCN9A Q15858 1/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ HRH3 Q9Y5N1 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ LIPE Q05469 1/20 0.40
▸ CYP3A4 P08684 3/20 0.39
▸ LIPG Q9Y5X9 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ DPP4 P27487 1/20 0.38
▸ DPP8 Q6V1X1 1/20 0.38
▸ DPP9 Q86TI2 1/20 0.38
▸ DPP7 Q9UHL4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14815145 1.00 TACR3 (0.47) TACR3SCN9AL3MBTL1DRD2DRD4
SCHEMBL14814987 0.87 ADRB1 (0.40) TACR3SCN9AL3MBTL1DRD2DRD4
SCHEMBL14814988 0.87 ADRB1 (0.40) TACR3SCN9AL3MBTL1DRD2DRD4
SCHEMBL14814827 0.83 ACACB (0.37) HRH3DPP4DPP9DPP7
SCHEMBL14814829 0.83 ACACB (0.37) HRH3DPP4DPP9DPP7
SCHEMBL14815243 0.80 DRD2 (0.46) TACR3SCN9AL3MBTL1DRD2DRD4
SCHEMBL14815181 0.74 MGLL (0.48) SCN9AKDM4EABL1LMNALIPE
SCHEMBL14816121 0.74 KDM4E (0.44) L3MBTL1KDM4ELMNAHPGD
SCHEMBL14816189 0.74 KDM4E (0.44) L3MBTL1KDM4ELMNAHPGD
SCHEMBL14815083 0.74 MGLL (0.48) SCN9AKDM4EABL1LMNALIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US claimed
US-8669255-B2 Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers ABBVIE INC. (US) 2014-03-11 — — US disclosed
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US disclosed
WO-2013049164-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1E, CACNA1D TACR3 321/4885SCN9A 298/4885L3MBTL1 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback